arrow
P

Peyman Hadji

université de montréal
H指数:48
被引数:9,342

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
2024-10-162
OAAI
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
2024-07-130
OAAI
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics- A retrospective analysis of a real world registry

根据患者和肿瘤特征的新发晚期乳腺癌患者的发生和特征-真实世界注册表的回顾性分析

2022-09-013
PRE
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

低水平HER2表达对临床HER2阴性患者预后的影响

2021-09-0148
PRE
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

在激素受体阳性,HER2阴性乳腺癌患者中,常规临床使用基于CDK4/6抑制剂的疗法与抗激素单药疗法的初步经验-来自PRAEGNANT research network的德国前两年药物可用性数据

BREAST
IF7.9
2020-12-0142
OAAI
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

患者和肿瘤特征对来曲唑治疗绝经后晚期乳腺癌妇女持续性的影响: 前瞻性观察性评估-TM研究的结果

2019-06-215
OAAI
Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167)
2019-02-151
PRE
Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167)
2019-02-150
PRE
PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/metastatic setting (NCT02338167)
2019-02-150
PRE
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
2019-02-013
OAAI
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial

依维莫司联合依西美坦治疗激素受体阳性、人表皮生长因子受体2阴性的局部晚期或转移性乳腺癌绝经后妇女的疗效和安全性: 单臂IIIB 4EVER期试验的结果

2018-10-3031
OAAI
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

原发性乳腺癌患者临床常规治疗中帕妥珠单抗联合化疗和曲妥珠单抗新辅助治疗的疗效多中心分析

2018-10-1535
PREAI